Home › Trials › NCT07556406
Clinical trial Recruiting at 1 site Observational Ages 55 and up

Central microperimetry and radial OCT in geographic atrophy

Official title: Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

Run by University of California, San Francisco · NCT07556406 · Data updated 2026-11-12

We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.

Quick facts

Study typeObservational
Ages55 Years and up
SexAll
Enrollment80 (estimated)
SponsorUniversity of California, San Francisco
Academic / other
Locations1 site (San Francisco, California)
StatusRecruiting
StartedJune 11, 2025
Main results expectedJune 11, 2027
Study endsJune 11, 2027
Registry record updatedApril 29, 2026
Trial IDNCT07556406 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 55 and older with intermediate AMD or with non-central geographic atrophy (GA not involving the foveal center) and at least 1% GA in the central 1 mm zone are ideal candidates.

Probably not a fit

Patients whose GA already involves the foveal center, who have very large baseline GA (>17.5 mm²), retinal atrophy from other causes, or who cannot undergo or complete imaging visits (including those unable to consent or with exclusionary conditions) are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective pilot at the University of California, San Francisco uses central microperimetry and radial OCT imaging to track structural and functional changes in patients with geographic atrophy (GA) or those at risk. Participants undergo repeated OCT and microperimetry to measure GA area and retinal sensitivity, with emphasis on progression toward the foveal center. The study enrolls adults aged 55 and older with non-central GA or intermediate AMD and excludes eyes with existing central foveal involvement or very large GA. Outcomes will compare whether combining radial OCT with central microperimetry gives finer measurement of central progression than standard approaches.

Why it matters

Potential benefit: If successful, these imaging approaches could detect central progression earlier or more precisely, helping clinicians monitor vision risk and time interventions better.

How similar studies have gone: Prior work has shown OCT and microperimetry can track structural and functional GA changes, but combining central microperimetry with radial OCT specifically to measure progression toward the fovea is a relatively novel pilot approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Subjects must be 55+ years of age Subjects in the "Intermediate AMD Observation Arm" must have intermediate age-related macular degeneration in one eye

Subjects in the "GA Observation Arm", "GA Continuing Treatment Arm", and "GA Treatment Arm" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.

Exclusion Criteria:

* Subjects with central involvement of GA. Central involvement is defined as geographic atrophy involving the foveal center point.

Subjects with a baseline size of GA \> 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas).

Subjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g/dL) on 5 or more days in the past month.

Evidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):

1. Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy
2. Branch or central retinal vein or artery occlusion
3. Macular hole
4. Pathologic myopia
5. Uveitis
6. Pseudovitelliform maculopathy
7. Intraoperative surgery within the last 90 days prior to study eye enrollment

Where it's running

  • University of California, San Francisco
    San Francisco, California, United States     Recruiting

Study contacts

  • Principal investigator: Jay Stewart, MD — University of California, San Francisco
  • Study coordinator: Jay M Stewart, MD
  • Email: eyestudy@ucsf.edu
  • Phone: (628) 206-3123

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Age-Related Macular Degeneration 111Geographic Atrophy 19University of California, San Francisco 3127
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.